Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 145914, 12 pages
http://dx.doi.org/10.1155/2015/145914
Research Article

Diene Valepotriates from Valeriana glechomifolia Prevent Lipopolysaccharide-Induced Sickness and Depressive-Like Behavior in Mice

1Programa de Pós Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil
2Programa de Pós Graduação em Neurociências, Universidade Federal do Rio Grande do Sul, 90046-900 Porto Alegre, RS, Brazil
3Faculdade de Veterinária, Universidade Federal do Rio Grande do Sul, 91540-000 Porto Alegre, RS, Brazil

Received 10 March 2015; Revised 24 May 2015; Accepted 26 May 2015

Academic Editor: David Mischoulon

Copyright © 2015 Liz G. Müller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, P. Berglund, O. Demler et al., “The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R),” Journal of the American Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Hannestad, N. Dellagioia, and M. Bloch, “The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis,” Neuropsychopharmacology, vol. 36, no. 12, pp. 2452–2459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Maes, I. Mihaylova, M. Kubera, M. Uytterhoeven, N. Vrydags, and E. Bosmans, “Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease,” Journal of Affective Disorders, vol. 125, no. 1–3, pp. 287–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Maes, “The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression,” Neuroendocrinology Letters, vol. 29, no. 3, pp. 287–291, 2008. View at Google Scholar · View at Scopus
  6. Y. Dowlati, N. Herrmann, W. Swardfager et al., “A meta-analysis of cytokines in major depression,” Biological Psychiatry, vol. 67, no. 5, pp. 446–457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. L. Raison and A. H. Miller, “Is depression an inflammatory disorder?” Current Psychiatry Reports, vol. 13, no. 6, pp. 467–475, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Shelton, J. Claiborne, M. Sidoryk-Wegrzynowicz et al., “Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression,” Molecular Psychiatry, vol. 16, no. 7, pp. 751–762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Mendlewicz, P. Kriwin, P. Oswald, D. Souery, S. Alboni, and N. Brunello, “Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study,” International Clinical Psychopharmacology, vol. 21, no. 4, pp. 227–231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Akhondzadeh, S. Jafari, F. Raisi et al., “Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial,” Depression and Anxiety, vol. 26, no. 7, pp. 607–611, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-H. Abbasi, F. Hosseini, A. Modabbernia, M. Ashrafi, and S. Akhondzadeh, “Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study,” Journal of Affective Disorders, vol. 141, no. 2-3, pp. 308–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Frenois, M. Moreau, J. O'Connor et al., “Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior,” Psychoneuroendocrinology, vol. 32, no. 5, pp. 516–531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. F. Viana, I. S. Maciel, F. N. Dornelles et al., “Kinin B1 receptors mediate depression-like behavior response in stressed mice treated with systemic E. coli lipopolysaccharide,” Journal of Neuroinflammation, vol. 7, article no. 98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Müller, A.-M. Myint, and M. J. Schwarz, “Inflammatory biomarkers and depression,” Neurotoxicity Research, vol. 19, no. 2, pp. 308–318, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. T. Ota and R. S. Duman, “Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression,” Neurobiology of Disease, vol. 57, pp. 28–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Saarelainen, P. Hendolin, G. Lucas et al., “Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects,” The Journal of Neuroscience, vol. 23, no. 1, pp. 349–357, 2003. View at Google Scholar · View at Scopus
  17. M. Adachi, M. Barrot, A. E. Autry, D. Theobald, and L. M. Monteggia, “Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy,” Biological Psychiatry, vol. 63, no. 7, pp. 642–649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. B. S. Ferreira Mello, A. S. Monte, R. S. McIntyre et al., “Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration,” Journal of Psychiatric Research, vol. 47, no. 10, pp. 1521–1529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Guo, P. Lin, X. Zhao et al., “Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice,” Neuroscience, vol. 263, pp. 1–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Ohgi, T. Futamura, T. Kikuchi, and K. Hashimoto, “Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration,” Pharmacology Biochemistry and Behavior, vol. 103, no. 4, pp. 853–859, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. M. Santiago, J. Barbiero, B. J. Martynhak et al., “Antidepressant-like effect of celecoxib piroxicam in rat models of depression,” Journal of Neural Transmission, vol. 121, no. 6, pp. 671–682, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Nöldner and K. Schötz, “Inhibition of lipopolysaccharid-induced sickness behavior by a dry extract from the roots of Pelargonium sidoides (EPs 7630) in mice,” Phytomedicine, vol. 14, no. 1, pp. 27–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. C. Veloso, A. D. Bitencourt, L. D. M. Cabral et al., “Pyrostegia venusta attenuate the sickness behavior induced by lipopolysaccharide in mice,” Journal of Ethnopharmacology, vol. 132, no. 1, pp. 355–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-M. Park, M.-S. Choi, N.-W. Sohn, and J.-W. Shin, “Ginsenoside Rg3 attenuates microglia activation following systemic lipopolysaccharide treatment in mice,” Biological & Pharmaceutical Bulletin, vol. 35, no. 9, pp. 1546–1552, 2012. View at Google Scholar · View at Scopus
  25. M. Hattesohl, B. Feistel, H. Sievers, R. Lehnfeld, M. Hegger, and H. Winterhoff, “Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties,” Phytomedicine, vol. 15, no. 1-2, pp. 2–15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Khuda, Z. Iqbal, A. Khan, F. Nasir, and Y. Shah, “Anti-inflammatory activity of the topical preparation of Valeriana wallichii and Achyranthes aspera leaves,” Pakistan Journal of Pharmaceutical Sciences, vol. 26, no. 3, pp. 451–454, 2013. View at Google Scholar · View at Scopus
  27. Z.-L. Zhang, Y.-M. Zuo, Q.-H. Wang, H.-B. Xiao, and H.-X. Kuang, “Effects of Valeriana amurensis on the expressions of iNOS, COX-2 and IkappaCB-alpha in Alzheimer's disease model rat's brain,” Zhong Yao Cai, vol. 33, no. 4, pp. 581–583, 2010. View at Google Scholar · View at Scopus
  28. A. Neamati, F. Chaman, M. Hosseini, and M. H. Boskabady, “The effects of Valeriana officinalis L. hydro-alcoholic extract on depression like behavior in ovalbumin sensitized rats,” Journal of Pharmacy and Bioallied Sciences, vol. 6, no. 2, pp. 97–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Subhan, N. Karim, A. H. Gilani, and R. D. E. Sewell, “Terpenoid content of Valeriana wallichii extracts and antidepressant-like response profiles,” Phytotherapy Research, vol. 24, no. 5, pp. 686–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. P. Sah, C. S. Mathela, and K. Chopra, “Antidepressant effect of Valeriana wallichii patchouli alcohol chemotype in mice: behavioural and biochemical evidence,” Journal of Ethnopharmacology, vol. 135, no. 1, pp. 197–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. D. A. Salles, A. L. Silva, S. B. Rech, N. Zanatta, and G. L. Von Poser, “Constituents of Valeriana glechomifolia Meyer,” Biochemical Systematics and Ecology, vol. 28, no. 9, pp. 907–910, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Geu-Flores, N. H. Sherden, V. Courdavault et al., “An alternative route to cyclic terpenes by reductive cyclization in iridoid biosynthesis,” Nature, vol. 491, no. 7427, pp. 138–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Andreatini and J. R. Leite, “Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal,” European Journal of Pharmacology, vol. 260, no. 2-3, pp. 233–235, 1994. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Backlund and T. Moritz, “Phylogenetic implications of an expanded valepotriate distribution in the Valerianaceae,” Biochemical Systematics and Ecology, vol. 26, no. 3, pp. 309–335, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Andreatini, V. A. Sartori, M. L. V. Seabra, and J. R. Leite, “Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study,” Phytotherapy Research, vol. 16, no. 7, pp. 650–654, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Maurmann, G. K. Reolon, S. B. Rech, A. G. Fett-Neto, and R. Roesler, “A valepotriate fraction of valeriana glechomifolia shows sedative and anxiolytic properties and impairs recognition but not aversive memory in mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 720853, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. L. G. Müller, L. A. Salles, A. C. Stein et al., “Antidepressant-like effect of Valeriana glechomifolia Meyer (Valerianaceae) in mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 36, no. 1, pp. 101–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Maes, “Evidence for an immune response in major depression: a review and hypothesis,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 19, no. 1, pp. 11–38, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Robinson, S. E. Edwards, S. Iyengar, F. Bymaster, M. Clark, and W. Katon, “Depression and pain,” Frontiers in Bioscience, vol. 14, no. 13, pp. 5031–5051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Cassel, R. M. F. Vargas, G. W. Brun et al., “Supercritical fluid extraction of alkaloids from Ilex paraguariensis St. Hil,” Journal of Food Engineering, vol. 100, no. 4, pp. 656–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. L. G. Müller, L. de Andrade Salles, S. Sakamoto et al., “Effect of storage time and conditions on the diene valepotriates content of the extract of Valeriana glechomifolia obtained by supercritical carbon dioxide,” Phytochemical Analysis, vol. 23, no. 3, pp. 222–227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. A. L. Silva, S. B. Rech, and G. L. Von Poser, “Quantitative determination of valepotriates from Valeriana native to South Brazil,” Planta Medica, vol. 68, no. 6, pp. 570–572, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. Ministério Público, Brasília, Brazil, Lei no. 11.794, de 8 de outubro de 2008, Publicada no DOU 9.10.2008.
  44. Ministério da Ciência, Tecnologia e Inovação, and CONCEA, “Diretrizes da prática de eutanásia do CONCEA,” Portaria no. 596, de 25 de junho de 2013, Brasília, Brazil, 2013.
  45. Ministério da Ciência, Tecnologia e Inovação, and CONCEA, “Diretriz brasileira para o cuidado e a utilização de animais para fins científicos e didáticos—DBCA,” Portaria no. 465, de 23 de maio de 2013, Brasília, Brazil, 2013.
  46. L. Steru, R. Chermat, B. Thierry, and P. Simon, “The tail suspension test: a new method for screening antidepressants in mice,” Psychopharmacology, vol. 85, no. 3, pp. 367–370, 1985. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Kwon, B. Lee, M. Kim, H. Lee, H.-J. Park, and D.-H. Hahm, “Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 2, pp. 265–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Neill and P. S. Dixon, “Effects of a preincisional 14-day course of valerian on natural killer cell activity in Sprague-Dawley male rats undergoing abdominal surgery,” Holistic Nursing Practice, vol. 21, no. 4, pp. 187–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Dantzer, “Cytokine-induced sickness behavior: where do we stand?” Brain, Behavior, and Immunity, vol. 15, no. 1, pp. 7–24, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-S. Lee, J.-H. Song, N.-W. Sohn, and J.-W. Shin, “Inhibitory effects of ginsenoside Rb1 on neuroinflammation following systemic lipopolysaccharide treatment in mice,” Phytotherapy Research, vol. 27, no. 9, pp. 1270–1276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. E. J. Nestler and W. A. Carlezon Jr., “The mesolimbic dopamine reward circuit in depression,” Biological Psychiatry, vol. 59, no. 12, pp. 1151–1159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Krishnan and E. J. Nestler, “The molecular neurobiology of depression,” Nature, vol. 455, no. 7215, pp. 894–902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. N. J. Jacobo-Herrera, N. Vartiainen, P. Bremner, S. Gibbons, J. Koistinaho, and M. Heinrich, “NF-κB modulators from Valeriana officinalis,” Phytotherapy Research, vol. 20, no. 10, pp. 917–919, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Lawrence, “The nuclear factor NF-κB pathway in inflammation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a001651, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. C. de Souza, C. Rossa Jr., G. P. Garlet, A. V. B. Nogueira, and J. A. Cirelli, “Modulation of host cell signaling pathways as a therapeutic approach in periodontal disease,” Journal of Applied Oral Science, vol. 20, no. 2, pp. 128–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Diamond, J. P. Kelly, and T. J. Connor, “Antidepressants suppress production of the Th1 cytokine interferon-γ, independent of monoamine transporter blockade,” European Neuropsychopharmacology, vol. 16, no. 7, pp. 481–490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Horikawa, T. A. Kato, Y. Mizoguchi et al., “Inhibitory effects of SSRIs on IFN-γ induced microglial activation through the regulation of intracellular calcium,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 7, pp. 1306–1316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Liu, Z. Wang, S. Liu, F. Wang, S. Zhao, and A. Hao, “Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells,” Neuropharmacology, vol. 61, no. 4, pp. 592–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Chen, C. Xie, H. Wang et al., “Sesquiterpenes inhibiting the microglial activation from laurus nobilis,” Journal of Agricultural and Food Chemistry, vol. 62, no. 20, pp. 4784–4788, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Jardón-Delgado, G. A. Magos-Guerrero, and M. Martínez-Vázquez, “Isolation of a new anti-inflammatory 20, 21, 22, 23, 24, 25, 26, 27-octanorcucurbitacin-typetriterpene from Ibervillea sonorae,” Natural Product Communications, vol. 9, no. 1, pp. 15–16, 2014. View at Google Scholar · View at Scopus
  61. U. R. Juergens, “Anti-inflammatory properties of the monoterpene 1.8-cineole: current evidence for co-medication in inflammatory airway diseases,” Drug Research, vol. 64, no. 12, pp. 638–646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. S.-A. Tang, H. Zhu, N. Qin et al., “Anti-inflammatory terpenes from flowers of Inula japonica,” Planta Medica, vol. 80, no. 7, pp. 583–589, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. A. L. Coppell, Q. Pei, and T. S. C. Zetterström, “Bi-phasic change in BDNF gene expression following antidepressant drug treatment,” Neuropharmacology, vol. 44, no. 7, pp. 903–910, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Molteni, F. Calabrese, F. Bedogni et al., “Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions,” International Journal of Neuropsychopharmacology, vol. 9, no. 3, pp. 307–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. R. S. Duman and L. M. Monteggia, “A neurotrophic model for stress-related mood disorders,” Biological Psychiatry, vol. 59, no. 12, pp. 1116–1127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Castrén, V. Võikar, and T. Rantamäki, “Role of neurotrophic factors in depression,” Current Opinion in Pharmacology, vol. 7, no. 1, pp. 18–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Martinowich, H. Manji, and B. Lu, “New insights into BDNF function in depression and anxiety,” Nature Neuroscience, vol. 10, no. 9, pp. 1089–1093, 2007. View at Publisher · View at Google Scholar · View at Scopus